CN113474349B - 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 - Google Patents

作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 Download PDF

Info

Publication number
CN113474349B
CN113474349B CN202080014726.4A CN202080014726A CN113474349B CN 113474349 B CN113474349 B CN 113474349B CN 202080014726 A CN202080014726 A CN 202080014726A CN 113474349 B CN113474349 B CN 113474349B
Authority
CN
China
Prior art keywords
compound
methyl
disease
pharmaceutically acceptable
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080014726.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113474349A (zh
Inventor
M.埃尔班
M.P.格洛戈夫斯基
M.C.科廷
B.G.劳霍恩
J.M.马修斯
J.R.帕特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to CN202410206971.5A priority Critical patent/CN118206566A/zh
Publication of CN113474349A publication Critical patent/CN113474349A/zh
Application granted granted Critical
Publication of CN113474349B publication Critical patent/CN113474349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080014726.4A 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 Active CN113474349B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410206971.5A CN118206566A (zh) 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962806201P 2019-02-15 2019-02-15
US62/806,201 2019-02-15
US201962931877P 2019-11-07 2019-11-07
US62/931,877 2019-11-07
PCT/IB2020/051100 WO2020165776A1 (en) 2019-02-15 2020-02-11 Hydroxypyridoxazepines as nrf2 activators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410206971.5A Division CN118206566A (zh) 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯

Publications (2)

Publication Number Publication Date
CN113474349A CN113474349A (zh) 2021-10-01
CN113474349B true CN113474349B (zh) 2024-03-01

Family

ID=69726636

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080014726.4A Active CN113474349B (zh) 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯
CN202410206971.5A Pending CN118206566A (zh) 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410206971.5A Pending CN118206566A (zh) 2019-02-15 2020-02-11 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯

Country Status (18)

Country Link
US (3) US11945826B2 (https=)
EP (1) EP3924356A1 (https=)
JP (1) JP7602469B2 (https=)
KR (1) KR102932313B1 (https=)
CN (2) CN113474349B (https=)
AU (1) AU2020222080C1 (https=)
BR (1) BR112021016042A2 (https=)
CA (1) CA3129955A1 (https=)
CL (1) CL2021002110A1 (https=)
CO (1) CO2021010930A2 (https=)
IL (2) IL313950A (https=)
MA (1) MA54939A (https=)
MX (1) MX2021009659A (https=)
MY (1) MY209603A (https=)
PH (1) PH12021551873A1 (https=)
SG (1) SG11202108257TA (https=)
TW (2) TWI843806B (https=)
WO (1) WO2020165776A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
KR102932313B1 (ko) * 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
AU2020283361B2 (en) * 2019-05-31 2025-11-27 Ube Corporation Benzotriazole derivative
CN118488944A (zh) 2022-01-07 2024-08-13 中外制药株式会社 具有Nrf2活化作用的含氮杂环化合物
US20250282724A1 (en) 2022-04-28 2025-09-11 Daiichi Sankyo Company, Limited Benzotriazole compound
JPWO2023210740A1 (https=) 2022-04-28 2023-11-02
EP4580612A1 (en) * 2022-09-02 2025-07-09 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease
CN121152792A (zh) 2023-06-19 2025-12-16 中外制药株式会社 具有Nrf2活化作用的含氮杂环化合物的晶体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202253A1 (en) * 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
CN108137557A (zh) * 2015-06-15 2018-06-08 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂
WO2018109647A1 (en) * 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018109642A1 (en) * 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714012B2 (en) * 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN104418834B (zh) * 2013-08-23 2017-09-15 重庆博腾制药科技股份有限公司 一种抗糖尿病药物中间体的合成方法
SG11201604611SA (en) 2013-12-18 2016-07-28 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
CN105272960A (zh) * 2014-07-18 2016-01-27 上海科胜药物研发有限公司 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法
WO2016178148A1 (en) * 2015-05-05 2016-11-10 Glenmark Pharmaceuticals Limited Process for preparation of dapagliflozin
CA2988373A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10364256B2 (en) * 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10913762B2 (en) * 2016-01-27 2021-02-09 Msn Laboratories Private Limited Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof
CA3044773A1 (en) * 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
KR102932313B1 (ko) * 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202253A1 (en) * 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
CN108137557A (zh) * 2015-06-15 2018-06-08 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
WO2018109642A1 (en) * 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109647A1 (en) * 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nrf2-Keap1蛋白相互作用小分子抑制剂的研究进展;姚争光等;《中国药物化学杂志》;第27卷(第4期);第325-333页 *

Also Published As

Publication number Publication date
KR102932313B1 (ko) 2026-02-26
CL2021002110A1 (es) 2022-02-11
MY209603A (en) 2025-07-24
MA54939A (fr) 2021-12-22
CA3129955A1 (en) 2020-08-20
TWI843806B (zh) 2024-06-01
CO2021010930A2 (es) 2021-09-09
TW202045514A (zh) 2020-12-16
US20250313573A1 (en) 2025-10-09
CN113474349A (zh) 2021-10-01
JP2022520442A (ja) 2022-03-30
WO2020165776A1 (en) 2020-08-20
MX2021009659A (es) 2021-09-08
CN118206566A (zh) 2024-06-18
TWI880702B (zh) 2025-04-11
US20240352034A1 (en) 2024-10-24
US11945826B2 (en) 2024-04-02
AU2020222080C1 (en) 2022-09-29
IL313950A (en) 2024-08-01
IL285438B2 (en) 2024-12-01
US20220204526A1 (en) 2022-06-30
AU2020222080B2 (en) 2022-05-19
TW202440593A (zh) 2024-10-16
IL285438B1 (en) 2024-08-01
PH12021551873A1 (en) 2022-05-23
BR112021016042A2 (pt) 2021-10-05
EP3924356A1 (en) 2021-12-22
JP7602469B2 (ja) 2024-12-18
KR20210126676A (ko) 2021-10-20
SG11202108257TA (en) 2021-08-30
IL285438A (en) 2021-09-30
AU2020222080A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CN113474349B (zh) 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯
EP4356969B1 (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
UA121271C2 (uk) Заміщені 3-азабіцикло[3.1.0]гексани як інгібітори кетогексокінази
JP2010518061A (ja) ムスカリンｍ３アンタゴニストのナパジシル酸塩
WO2013036464A1 (en) Gamma secretase inhibitors
EP3101020B1 (en) Deuterated quinazolinone compound and pharmaceutical composition comprising same
EP3796906A1 (en) Indanes as nrf2 activators
CN120019059A (zh) 新型acc抑制剂
WO2015026693A1 (en) 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP4027999B1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
RU2812931C2 (ru) Гидроксипиридоксазепины в качестве активаторов nrf2
HK40106672A (zh) 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯
CN121969620A (zh) 作为激酶抑制剂的三唑并吡啶醚连接的化合物
WO2025122859A1 (en) Indazole-based macrocyclic compounds
JPWO2006088080A1 (ja) シクロヘプタ［ｂ］ピリジン−３−カルボニルグアニジン誘導体およびそれを含有する医薬品
JP2016216446A (ja) ピロリジン−２，５−ジオン誘導体の多形形態、医薬組成物、およびｉｄｏ１阻害薬としての使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant